大元泵业公告 扬子晚报网2月26日讯(记者范晓林薄云峰)2月25日盘后，大元泵业（603757）发布公告称，其董事会收到公司实际控制人之一韩元再先生家属通知，韩元 再先生于近日不幸逝世。 大元泵业称，韩元再先生作为公司的创始人和实际控制人之一，自公司创立以来始终支持公司的经营发展战略，为公司创立、成长、发展壮大作出了巨大 贡献。公司董事、高级管理人员以及全体员工对韩元再先生的辛勤付出和卓越贡献致以崇高敬意和衷心感谢，对韩元再先生的逝世表示沉痛哀悼和深切缅 怀，并向其家属致以深切慰问。 截至公告披露日，韩元再持有公司2108.96万股股份，占公司总股本的11.31%，为公司5名实际控制人之一。 韩元再逝世后，其所持有的公司股份后续将按照相关法律法规进行处置，相关手续办理完成后预计将导致公司实际控制人的构成发生变化。 大元泵业表示，目前，公司生产经营活动正常。公开资料显示，韩元再，男，1955年出生，是大元泵业的创始团队核心成员之一。从现有信息看，韩元再 近年来已逐步退出一线管理岗位。大元泵业主营业务是各类泵的研发、生产、销售及提供相关服务，公司2017年上市。 校对盛媛媛 查阅股东信息发现，韩元再与其他四位股东 ...

【导读】大元泵业实控人之一韩元再不幸逝世 2月25日盘后，浙江大元泵业（603757）股份有限公司（以下简称大元泵业）发布公告称，其董事会收到公司实际控制人之一韩元再先生家属通 知，韩元再先生于近日不幸逝世。 大元泵业称，韩元再先生作为公司的创始人和实际控制人之一，自公司创立以来始终支持公司的经营发展战略，为公司创立、成长、发展壮大作 出了巨大贡献。公司董事、高级管理人员以及全体员工对韩元再先生的辛勤付出和卓越贡献致以崇高敬意和衷心感谢，对韩元再先生的逝世表示 沉痛哀悼和深切缅怀，并向其家属致以深切慰问。 公开信息显示，韩元再出生于1955年6月，曾任大元金属执行董事兼法定代表人、大元石油监事、大元有限监事会主席、大元金属执行董事兼经 理、上海新沪董事兼总经理等职务。韩元再曾在大元泵业担任监事会主席多年，于2021年6月届满离任。 韩元再持有大元泵业2108.96万股股份，占总股本的11.31%，为大元泵业5名实际控制人之一。据悉，韩元再、韩元平、韩元富、王国良、徐伟建 构成一致行动关系，为大元泵业的控股股东及实际控制人。其中，韩元再、韩元平与韩元富为兄弟关系。目前，韩元平为大元泵业的董事长。 | 序号 | ...

【导读】胜通能源筹划易主，12月5日起停牌 中国基金报记者 夏天 上市三年后， 胜通能源 （证券代码：001331）拟易主。 12月5日午间，胜通能源公告称，公司控股股东、实际控制人魏吉胜已签署了股份转让意向书，该事项可能导致公司控股股东、实际控制人 发生变更。 公开资料显示，胜通能源成立于2012年，2022年9月在深交所挂牌上市，主营业务为LNG（液化天然气）的采购、运输、销售以及原油、 普货的运输服务。 截至2025年三季度末，魏吉胜直接持有胜通能源1.04亿股，持股占比 为 36.97%，系公司第一大股东，期末参考市值约 为 14.4亿元。 | 十大股东明细 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 时间范围 | | | | | | | 11时间排序 | [ = =出到excel | | 2025年三季报 | | | | | | | | 查看图形 | | 股东各称 | 股东性质 | 期末参考市值 (亿元) | 持股数量(股) | 持股比例 (%) | 較上期持股变 动数(設) | 持設比例变动 ...

Core Viewpoint - The actual controller of Guosheng Securities will change to Jiangxi Provincial State-owned Assets Supervision and Administration Commission following a free transfer of shares from its controlling shareholder, Jiangxi Jiaotou [2] Group 1: Share Transfer Details - Guosheng Securities announced that its controlling shareholder, Jiangxi Jiaotou, will transfer 90% of its shares to Jiangxi Provincial State-owned Assets Supervision and Administration Commission without compensation [2] - The transfer has been approved by the Jiangxi Provincial Government and will result in Jiangxi Provincial State-owned Assets Supervision and Administration Commission directly holding the shares [2] Group 2: Ownership Structure - After the transfer, Jiangxi Provincial State-owned Assets Supervision and Administration Commission will hold 90% of Jiangxi Jiaotou's shares, while Jiangxi Jiaotou's ownership stake in Guosheng Securities will remain unchanged [2] - The controlling shareholder of Guosheng Securities will still be Jiangxi Jiaotou, but the actual controller will shift from Jiangxi Provincial Department of Transportation to Jiangxi Provincial State-owned Assets Supervision and Administration Commission [2]

人民财讯10月31日电，中元股份（300018）10月31日公告，10月30日，公司实控人尹健等8人与朱双 全、朱顺全签订《表决权委托协议》，尹健等8人将合计持有中元股份1.01亿股股份的表决权委托给朱 双全、朱顺全行使。同日，朱双全、朱顺全、朱梦茜与尹健等8人签署一致行动协议，约定表决权委托 期间，尹健等8人成为朱双全、朱顺全、朱梦茜的一致行动人。《表决权委托协议》生效后，朱双全、 朱顺全持有上市公司的表决权比例为20.71%。截至10月30日，朱梦茜直接持有上市公司的股权比例为 4.92%。10月30日，朱双全、朱顺全、朱梦茜签署《一致行动协议》，朱双全、朱顺全、朱梦茜为一致 行动人，合计持有上市公司的表决权比例为25.63%，上市公司实控人变更为朱双全、朱顺全及朱梦 茜。公司股票自11月3日起复牌。 ...

Core Viewpoint - The recent criminal detention of Xu Xiren, the chairman and president of Beijing University Pharmaceutical, raises significant concerns regarding the company's management stability and future operations [1][10]. Group 1: Management Changes - Xu Xiren was recently detained, which has led to a temporary delegation of his responsibilities to other executives [1][10]. - The company underwent a major management reshuffle earlier this year, with several key executives resigning or being removed from their positions [11][15]. Group 2: Ownership and Financial Transactions - Xu Xiren acquired control of Beijing University Pharmaceutical for a nominal price of 1 yuan, gaining a 22.22% stake in the company through a complex transaction involving the acquisition of Southwest Synthetic Pharmaceutical Group [4][6]. - The deal included the transfer of over 24 billion yuan in debt, which poses potential financial risks for the company [7][8]. Group 3: Business Challenges - The company is facing pressure to dissociate from its historical ties to Peking University and Ping An Insurance, which may impact its brand and business operations [9][10]. - A significant portion of the company's revenue has been historically dependent on its partnership with Peking University International Hospital, which has recently been terminated, leading to potential revenue losses estimated at 6 billion yuan for the latter half of 2025 [10][9]. Group 4: Market and Financial Performance - For the year 2024, the company reported total revenue of 2.06 billion yuan and a net profit of 127 million yuan, indicating a challenging financial landscape ahead [10]. - The anticipated revenue decline due to the termination of key partnerships could lead to a significant drop in net profit, with projections indicating a decrease of approximately 680 million yuan starting in 2026 [10].

Core Viewpoint - The board of North China Pharmaceutical (000788.SZ) has proposed to remove director Mao Run due to his resignation from Southwest Synthesis Pharmaceutical Group, which he opposed, citing legal grounds for his dismissal [1][2][4]. Group 1: Board Changes - Mao Run was proposed to be removed from the board as he no longer represents Southwest Synthesis due to his resignation from executive roles [2][3]. - The board voted to remove Mao Run with 8 votes in favor and 1 against, highlighting a significant shift in board composition following the change in actual control of the company [2][6]. - The newly elected non-independent director is Huang Lianjun, who has connections to the new controlling shareholder [3][4]. Group 2: Changes in Control - The actual control of North China Pharmaceutical changed hands in December 2023 when New Advantage acquired 100% of Southwest Synthesis from the Ping An Group [4][5]. - Following the acquisition, there have been multiple personnel changes within the board, indicating a strategic shift under new management [6][7]. - The new controlling entity has maintained a consistent operational strategy despite changes in ownership, focusing on core pharmaceutical areas [7][8]. Group 3: Financial Performance - North China Pharmaceutical's revenue from pharmaceutical distribution increased to nearly 70% in 2024, reflecting a strategic focus on this segment [8]. - The company's revenue decreased from 2.237 billion yuan in 2021 to 2.060 billion yuan in 2024, while net profit rose from 43.14 million yuan to 138 million yuan during the same period, marking a historical high [7][8].